Related Experiment Video
Updated: Mar 15, 2026

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Population Pharmacodynamic Model for Bayesian Prediction of Myelosuppression Profiles Based on Routine Clinical Data
Yugo Chisaki1, Tomohiro Terada, Yoshitaka Yano
1Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical University, Kyoto, Japan.
Background:
Hematological toxicity is a serious adverse event and is often a dose-limiting factor in anticancer drugs. The objective of the present study was to develop a modeling and simulation (M&S) procedure for predictions of time course profiles of blood cell counts that reflect myelosuppression profiles.
Methods:
A method for Bayesian prediction of myelosuppression profiles during chemotherapy using a population pharmacodynamic model is proposed, and predictabilities of nadir values and times to nadir (Tnadir) after gemcitabine and carboplatin treatment were evaluated. The model is based on an equation for Erlang distribution, which we previously proposed, and it explains time course profiles of platelet (PLT), red blood cell (RBC) and white blood cell (WBC).
Results And Conclusion:
PLT, RBC and WBC counts were retrospectively collected from 61 time courses (a total of 472 points) of 27 cancer patients. Predictive performance by a one-point Bayesian prediction was evaluated using data from day 8 in consideration of applicability to outpatients. Some good predictability was obtained for nadir values with some exceptions for PLT and RBC, whereas the predictability of Tnadir was insufficient. Although the predictability was not acceptable enough, this M&S approach could be used for supportive care during cancer chemotherapy.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacodynamic Models: Overview
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Dosage Regimens: Partial Pharmacokinetic Parameters

